Review



anti pd 1 antibody  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress anti pd 1 antibody
    Anti Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1 antibody/product/MedChemExpress
    Average 94 stars, based on 10 article reviews
    anti pd 1 antibody - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    anti pd 1 antibody  (MedChemExpress)
    94
    MedChemExpress anti pd 1 antibody
    Anti Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1 antibody/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anti pd 1 antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    anti mouse pd 1 antibodies  (MedChemExpress)
    94
    MedChemExpress anti mouse pd 1 antibodies
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    Anti Mouse Pd 1 Antibodies, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pd 1 antibodies/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anti mouse pd 1 antibodies - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    anti mouse pd 1 antibody  (MedChemExpress)
    94
    MedChemExpress anti mouse pd 1 antibody
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    Anti Mouse Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pd 1 antibody/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anti mouse pd 1 antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    αpd 1  (MedChemExpress)
    95
    MedChemExpress αpd 1
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    αpd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/αpd 1/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    αpd 1 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    anti mouse pd 1 antibody rmp1 14  (MedChemExpress)
    94
    MedChemExpress anti mouse pd 1 antibody rmp1 14
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    Anti Mouse Pd 1 Antibody Rmp1 14, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pd 1 antibody rmp1 14/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anti mouse pd 1 antibody rmp1 14 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    mouse anti ccr5  (MedChemExpress)
    94
    MedChemExpress mouse anti ccr5
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    Mouse Anti Ccr5, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti ccr5/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    mouse anti ccr5 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    mouse anti pd l1 antibody  (Proteintech)
    96
    Proteintech mouse anti pd l1 antibody
    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the <t>anti-PD-1</t> group.
    Mouse Anti Pd L1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti pd l1 antibody/product/Proteintech
    Average 96 stars, based on 1 article reviews
    mouse anti pd l1 antibody - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

    Journal: Materials Today Bio

    Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

    doi: 10.1016/j.mtbio.2025.102749

    Figure Lengend Snippet: Systemic antitumor immune modulation and combined immune checkpoint blockade (ICB) therapy mediated by Fe 3 O 4 NPs@Met-GA-H. ( A ) Schematic illustration of the experimental timeline for treating B16F10 tumor-bearing C57BL/6 mice. ( B ) Representative images of excised tumors from each treatment group (n = 5). ( C ) Tumor growth curves across different treatments (n = 5). ( D ) Tumor inhibition rates following various treatments (n = 5). ( E ). Proposed mechanism of Fe 3 O 4 NPs@Met-GA-H-induced immune activation and tumor suppression. ( F ) Spleens collected from each group (n = 5). ( G ) Spleen weights under different treatment conditions (n = 5). ( H, I ) Flow cytometry analysis of CD80 + CD86 + expression (H) and MHC-II (I) expression in splenic DCs (n = 5). ( J ) Flow cytometry assay of CD4 + and CD8 + expression (gated on CD3 + ) from splenocytes (n = 5). ( K ) Flow cytometry analysis of CD86 + CD206 − and CD86 − CD206 + macrophages (gated on F4/80 + ) in tumors (n = 5). ( L, M ) Quantitative analysis of CD80 + CD86 DCs (L) and MHC-II DCs (M) in spleens (n = 5). ( N, O ) Quantitative analysis of CD4 + (N) and CD8 + (O) T-cell populations in spleen (n = 5). ( P ) Ratio of CD86 + CD206 − to CD86 − CD206 + (gated on F4/80 + ) tumor-associated macrophages (n = 5). Data are presented as mean ± SD. Statistical significance was determined using Student's t-test for pairwise comparisons and one-way ANOVA for multiple groups. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl group. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the anti-PD-1 group.

    Article Snippet: Anti-mouse PD-1 antibodies (Cat. No. S-5001) were obtained from MedChemExpress.

    Techniques: Inhibition, Activation Assay, Flow Cytometry, Expressing